Bright Biologics develops bispecific and multispecific therapeutic antibodies using a VHH antibody discovery platform to enhance treatment efficacy for cancer patients facing resistance to conventional therapies. Their focus on creating novel antibody-drug conjugates and T-cell engagers targets the heterogeneity of solid tumors, which are a primary cause of treatment failure.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancer patients develop resistance to conventional therapies due to the heterogeneity of solid tumors, where monospecific tumor-associated antigen targeting therapies only kill one subpopulation of cancer cells, leading to tumor relapse. Current treatment options often fail to address this complexity, resulting in unmet medical needs and poor clinical outcomes.
Solution
Bright Biologics is developing next-generation bispecific and multispecific antibody drugs using VHH antibodies as building blocks to improve clinical outcomes for cancer patients with resistance and/or unmet medical needs. The company focuses on creating novel bispecific antibody-drug conjugates and T-cell engagers that target the heterogeneity of solid tumors. This approach aims to overcome the limitations of monospecific therapies by simultaneously targeting multiple subpopulations of cancer cells, potentially leading to more effective and durable responses.
Target Audience
The primary target audience includes cancer patients facing resistance to conventional therapies and those with unmet medical needs, as well as oncologists and researchers seeking more effective treatment options for solid tumors.
Features
- Utilizes VHH antibodies as building blocks for bispecific and multispecific antibody drugs.
- Developing novel bispecific antibody-drug conjugates.
- Developing T-cell engagers to target multiple subpopulations of cancer cells.
- Focus on solid tumors and addressing tumor heterogeneity.